12:00 AM
 | 
Nov 25, 2013
 |  BioCentury  |  Finance

Bugs in the clinic

Newco Seres first to the clinic in microbiome space, targeting C. difficile
Bugs in the clinic

Newco Seres Health Inc. has emerged from stealth mode, and the Flagship Ventures startup believes it already has at least one leg up on other microbiome companies - a program in the clinic.

Seres has been operating out of Flagship VentureLabs for two and a half years, CEO David Berry told BioCentury. Last week, the company disclosed it had raised $10.5 million in a series A round led by Flagship with participation...

Read the full 356 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >